GlassScriptPhysician profile
Creagh E Milford
NPI 1215920764
$4,950.09
in general payments reported to CMS, 2019-2025
32 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $313 · 2021: $596 · 2022: $845 · 2023: $1,029 · 2024: $717 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Consulting Fee: $15.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.44 |
| Consulting Fee | $15.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $688.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $581.99 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $545.00 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $403.04 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $377.59 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $285.33 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $216.90 | 2023-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $206.70 | 2019-2024 | Brilinta, Farxiga |
| Pfizer INC. | $188.51 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $147.38 | 2019-2023 | |
| Boston Scientific Corporation | $147.00 | 2020-2025 | Watchman Flx, Watchman Access System |
| Astellas Pharma US INC | $138.57 | 2019-2021 | |
| Bracco Diagnostics INC. | $121.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.61 | 2023-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $96.42 | 2019-2025 | Uptravi, Opsumit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $94.48 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $92.52 | 2022-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $76.10 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bridgebio Pharma, INC. | $65.95 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $49.31 | 2025 | |
| Abbott Laboratories | $48.98 | 2025 | Amplatzer Amulet, Cardiomems |
| Alnylam Pharmaceuticals INC. | $42.87 | 2023 | Onpattro |
| Abiomed | $33.08 | 2023-2024 | Impella |
| Kestra Medical Technology Services, INC. | $31.01 | 2023 | Assure Wcd |
| Baxter Healthcare | $31.01 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $27.77 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $27.08 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $22.61 | 2024 | Arcalyst |
| Philips North America LLC | $17.18 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2021 | |
| Daiichi Sankyo INC. | $13.96 | 2021 | |
| Medtronic, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Creagh Milford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.